• Product name
  • Description
    Rabbit polyclonal to JAK2
  • Host species
  • Specificity
    ab39636 detects endogenous levels of total JAK2 protein.
  • Tested applications
    Suitable for: IHC-P, IHC-Fr, WB, ELISAmore details
  • Species reactivity
    Reacts with: Mouse, Rat, Dog, Human
  • Immunogen

    Synthetic peptide (Human) derived from JAK2 around the phosphorylation site of Tyrosine 221.

  • Positive control
    • IHC-P: Human breast carcinoma tissue; Dog lung tissue. K562 cell lysate for WB.



Our Abpromise guarantee covers the use of ab39636 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
IHC-P 1/50 - 1/100.
IHC-Fr Use at an assay dependent concentration. PubMed: 21420414
WB 1/500 - 1/1000.
ELISA 1/20000.


  • Function
    Non-receptor tyrosine kinase involved in various processes such as cell cycle progression, apoptosis, mitotic recombination, genetic instability and histone modifications. In the cytoplasm, plays a pivotal role in signal transduction via its association with cytokine receptors, which constitutes an initiating step in signaling for many members of the cytokine receptor superfamily including the receptors for growth hormone (GHR), prolactin (PRLR), leptin (LEPR), erythropoietin (EPOR), granulocyte-macrophage colony-stimulating factor (CSF2), thrombopoietin (THPO) and multiple interleukins. Following stimulation with erythropoietin (EPO) during erythropoiesis, it is autophosphorylated and activated, leading to its association with erythropoietin receptor (EPOR) and tyrosine phosphorylation of residues in the EPOR cytoplasmic domain. Also involved in promoting the localization of EPOR to the plasma membrane. Also acts downstream of some G-protein coupled receptors. Plays a role in the control of body weight (By similarity). Mediates angiotensin-2-induced ARHGEF1 phosphorylation. In the nucleus, plays a key role in chromatin by specifically mediating phosphorylation of 'Tyr-41' of histone H3 (H3Y41ph), a specific tag that promotes exclusion of CBX5 (HP1 alpha) from chromatin.
  • Tissue specificity
    Expressed in blood, bone marrow and lymph node.
  • Involvement in disease
    Note=Chromosomal aberrations involving JAK2 are found in both chronic and acute forms of eosinophilic, lymphoblastic and myeloid leukemia. Translocation t(8;9)(p22;p24) with PCM1 links the protein kinase domain of JAK2 to the major portion of PCM1. Translocation t(9;12)(p24;p13) with ETV6.
    Defects in JAK2 are a cause of susceptibility to Budd-Chiari syndrome (BCS) [MIM:600880]. It is a syndrome caused by obstruction of hepatic venous outflow involving either the hepatic veins or the terminal segment of the inferior vena cava. Obstructions are generally caused by thrombosis and lead to hepatic congestion and ischemic necrosis. Clinical manifestations observed in the majority of patients include hepatomegaly, right upper quadrant pain and abdominal ascites. Budd-Chiari syndrome is associated with a combination of disease states including primary myeloproliferative syndromes and thrombophilia due to factor V Leiden, protein C deficiency and antithrombin III deficiency. Budd-Chiari syndrome is a rare but typical complication in patients with polycythemia vera.
    Defects in JAK2 are a cause of polycythemia vera (PV) [MIM:263300]. A myeloproliferative disorder characterized by abnormal proliferation of all hematopoietic bone marrow elements, erythroid hyperplasia, an absolute increase in total blood volume, but also by myeloid leukocytosis, thrombocytosis and splenomegaly.
    Defects in JAK2 gene may be a cause of essential thrombocythemia (ET) [MIM:187950]. ET is characterized by elevated platelet levels due to sustained proliferation of megakaryocytes, and frequently lead to thrombotic and haemorrhagic complications.
    Defects in JAK2 are a cause of myelofibrosis (MYELOF) [MIM:254450]. Myelofibrosis is a disorder characterized by replacement of the bone marrow by fibrous tissue, occurring in association with a myeloproliferative disorder. Clinical manifestations may include anemia, pallor, splenomegaly, hypermetabolic state, petechiae, ecchymosis, bleeding, lymphadenopathy, hepatomegaly, portal hypertension.
    Defects in JAK2 are a cause of acute myelogenous leukemia (AML) [MIM:601626]. AML is a malignant disease in which hematopoietic precursors are arrested in an early stage of development.
  • Sequence similarities
    Belongs to the protein kinase superfamily. Tyr protein kinase family. JAK subfamily.
    Contains 1 FERM domain.
    Contains 1 protein kinase domain.
    Contains 1 SH2 domain.
  • Domain
    Possesses 2 protein kinase domains. The second one probably contains the catalytic domain, while the presence of slight differences suggest a different role for protein kinase 1.
  • Post-translational
    Autophosphorylated, leading to regulate its activity. Leptin promotes phosphorylation on tyrosine residues, including phosphorylation on Tyr-813. Autophosphorylation on Tyr-119 in response to EPO down-regulates its kinase activity. Autophosphorylation on Tyr-868, Tyr-966 and Tyr-972 in response to growth hormone (GH) are required for maximal kinase activity.
  • Cellular localization
    Endomembrane system. Nucleus.
  • Information by UniProt
  • Database links
  • Alternative names
    • JAK 2 antibody
    • JAK-2 antibody
    • JAK2 antibody
    • JAK2_HUMAN antibody
    • Janus Activating Kinase 2 antibody
    • Janus kinase 2 (a protein tyrosine kinase) antibody
    • Janus kinase 2 antibody
    • JTK 10 antibody
    • JTK10 antibody
    • kinase Jak2 antibody
    • OTTHUMP00000043260 antibody
    • THCYT3 antibody
    • Tyrosine protein kinase JAK2 antibody
    • Tyrosine-protein kinase JAK2 antibody
    see all


  • ab39636 at a 1/50 dilution, staining JAK2 in human breast carcinoma by Immunohistochemistry, Paraffin embedded tissue. Left image shows section without blocking peptide. Right image shows section with blocking peptide.
  • All lanes : Anti-JAK2 antibody (ab39636) at 1/500 dilution

    Lane 1 : K562 cells
    Lane 2 : K562 cells with Blocked with immunising peptide

    Lysates/proteins at 15 µg per lane.
  • Formalin-fixed, paraffin-embedded dog lung tissue stained fo JAK2 using ab39636 at 1/400 dilution in immunohistochemical analysis. Primary antibosy was incubated for 30 minutes at 20°C.

    Heat mediated antigen retrieval was performed using 1 mM EDTA buffer pH 8.


This product has been referenced in:
  • He L  et al. Local blockage of self-sustainable erythropoietin signaling suppresses tumor progression in non-small cell lung cancer. Oncotarget 8:82352-82365 (2017). Read more (PubMed: 29137269) »
  • Luo LN  et al. Osthole decreases renal ischemia-reperfusion injury by suppressing JAK2/STAT3 signaling activation. Exp Ther Med 12:2009-2014 (2016). WB ; Rat . Read more (PubMed: 27698686) »
See all 10 Publications for this product

Customer reviews and Q&As

1-4 of 4 Abreviews or Q&A


Thank you for bringing this to our attention. I am sorry to read that two of the antibodies you purchased are not staining blots of your mouse liver samples.

I am assuming the transfer from gel to blot was effective, if your protocol worked with other blots of these samples.

I recommend stripping a blot and re-blocking with 1% BSA without detergent for one hour, and also diluting the antibodies in this 1% BSA solution, instead of non-fat dry milk. I also recommend trying the antibodies at higher concentrations, for instance 1/250 for anti-JAK2 ab39636, and 1/2000 for the phospho-Jak2 antibody, ab32101.

Please let me know the results. If this modification fails, I will be happy to provide replacements, or a credit or refund. The phosphorylation in the liver may be difficult to detect if it is not induced. If possible, I recommend including a positive control such as the treated mouse liver sample shown on the datasheet of ab68268.

Click here (or use the following: https://www.abcam.com/index.html?datasheet=68268).

Read More


Thank you for taking the time to complete our questionnaire and contact us. I am sorry to hear you have had difficulty obtaining satisfactory results from this antibody.

I appreciate the time you have spent in the laboratory and understand your concerns. It is regrettable the results have not been successful.

I would like to reassure you that this antibody is tested and covered by our guarantee for IHC-P, IHC-Fr and and in Mouse, Rat, Dog and Human samples.In the event that a product is not functioning in the tested applications and species cited on the product data sheet (and the problem has been reported within 6 months of purchase), we will be pleased to provide a credit note, free of charge replacement or refund.

In this case, I woudl be pleased to provide afree of charge replacement or credit note in compensation if the antibody has been used in a tested species.

I would also appreciate if you are able to provide some further information which is beneificial for our quality monitoring records:

1. Which type of tissue has been tested?

2. What dilutions has the antibody been used at?

Thank you for your cooperation. I look forward to hearing from you with details of how you would like to proceed.

Read More


Thank you for contacting us. The treatment of PFA-fixed, paraffin embedded sections (IHC-P) before incubation with priamry antibody would include antigen retrieval, blocking of endogenous peroxidases (if HRP is being used for detection), and blocking of non-specific proteins. Here are the protocol details for the respective antibodies: ab30646, ab31370, ab39636, ab59389: 1. antigen retrieval: 10 mM citrate buffer (pH6.0) boil in pressure cooker 2. block with 3% H2O2 (in fresh methanol) for 15 minutes at room temperature 3. block with 3% BSA in TBS for 30 minutes ab6672: antigen retrieval: citrate buffer pH 6 and proteinase K digestion have been tried successfully as well as no antigen retrieval. 2. block with 3% hydrogen peroxide for 10 min 3. block with 1-10% Serum for up to 1 hour ab32101: 1. antigen retrieval:10 mM Sodium Citrate Buffer, pH 6.0 in rice cooker 2. block with 3% hydrogen peroxide for 10 min 3. block with PBS + 10% serum I hope this information is helpful to you. Please do not hesitate to contact us if you need any more advice or information.

Read More
Abcam guarantees this product to work in the species/application used in this Abreview.
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections)
Dog Tissue sections (Lung)
10% Buffered Formalin
Antigen retrieval step
Heat mediated - Buffer/Enzyme Used: 1mM EDTA buffer (pH8)
Blocking step
Menapath Protein Block as blocking agent for 15 minute(s) · Concentration: 100% · Temperature: 20°C

Abcam user community

Verified customer

Submitted Apr 23 2010


Sign up